Oncología (médica)

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. A Study To Explore Tumor Biology In Metastatic Esophageal And Gastric Cancer Patients

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to the biopsy performed prior to cancer treatment.

2. Iberdomide, Daratumumab, Bortezomib, And Dexamethasone For Treatment Of Newly Diagnosed Multiple Myeloma, IDEAL Study

   Rochester, Minn.

   The purpose of this study is to find the maximum tolerated dose of iberdomide for patients newly diagnosed with multiple myeloma,  and to determine response rate during induction treatment when combined with daratumumab, bortezomib and dexamethansone. 

3. Image-based Mapping Of Brain Tumors

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment.

    

4. Actinium Therapy For Late-stage Aggressive Sarcomas

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma.
   
   The main questions the study aims to answer in Phase/Part 1 of the trial are:
   
   * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.
   * What is the most tolerable dose of \[Ac225\]RTX-2358
   * Does the treatment show effectiveness on advanced sarcoma
   
   Participants will:
   
   * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months
   * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.
   * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests
   * Remain in long term follow-up for a period of four additional years

5. 3D Ultrasound Imaging For Breast Cancer Diagnosis

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveess of a new 3D ultrasound imaging technology combining B-mode, microvessel imaging, shear wave elastography, and machine learning for breast lesion diagnosis.

6. Testicular Tissue Cryopreservation In Children

   Rochester, Minn.

   This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.

7. Long-Term Follow-up Protocol For Participants Treated With Gene-Modified T Cells

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
   
   Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

8. A Study To Evaluate The Safety And Effectiveness Of Idecabtagene Vicleucel To Treat Multiple Myeloma

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information. 

9. A Study Of Clonal Hematopoiesis (CH) And Hematological Toxicity After Cancer Treatment

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The overall objective of this project is to combine robust clinical data (e.g. prior chemotherapy or radiation exposure, cumulative radiotheranostic dose) with geneticclonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in radiotheranostic treated solid tumor patients.

10. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

    Jacksonville, Fla.

    UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion for patients once every four weeks. Patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer expressing high levels of NaPi2b.